NEW YORK, NY, Biotechnology company developing a novel drug class targeting RNA-modifying proteins, debuted today with a $54 million Series A financing.
Gotham Therapeutics Launches with $54M Series A
NEW YORK, NY, Biotechnology company developing a novel drug class targeting RNA-modifying proteins, debuted today with a $54 million Series A financing.
